Backstrom Jay T. - 13 Feb 2025 Form 4 Insider Report for LAVA Therapeutics NV (LVTX)

Reporting relationship: Director
Issuer ticker: LVTX
Reported as of: 13 Feb 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Feb 2025, 20:15:15 UTC
Prior SEC filing: 21 Jan 2025
Next SEC filing: 20 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Amy Garabedian, Attorney-in-Fact

Key filing fact

Backstrom Jay T. filed Form 4 for LAVA Therapeutics NV (LVTX) on 18 Feb 2025.

Key facts

This page summarizes Backstrom Jay T.'s Form 4 filing for LAVA Therapeutics NV (LVTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Feb 2025, 20:15.

Change

Previous filing in this sequence was filed on 21 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LVTX transaction Derivative

Common Shares (Right to Buy)

Award

Transaction value: $0
Shares: +33,390
Change %
Price: $0.000000
Shares after: 33,390
Date: 13 Feb 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 33,390
Exercise price: $0.9300
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

100% of the shares underlying the option will vest on February 13, 2026, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on such vesting date.